Table 1

Patients	Gender/Age/ Clinical outcome	Diagnosis of SS	Initiation and length of treatment with Aprepitant	Previous antipruritic therapy	Previous therapy for SS	DLQI and VAS scores before and after treatment with Aprepitant
Patient 1 †	F/68 Initial good response	11/2010	11/03/11 4 weeks	TCS Antihistamines Antidepressant Thalidomide PUVA	Alemtuzumab	Before treatment: DLQI: 23 VAS: 10 After treatment: DLQI: 21 VAS: 8
Patient 2	M/65 Response	01/2010	10/02/2011 4 weeks	TCS Antihistamines Antidepressant	CVP Alemtuzumab	Before treatment: DLQI: 18 VAS: 9 After treatment: DLQI: 3 VAS: 0
Patient 3	F/70 Response	07/2009	05/11/2010 ‡ 21 weeks	TCS Antihistamines PUVA	Bexarotene INF-α CHOP Alemtuzumab	Before treatment: DLQI: 22 VAS: 9 After treatment: DLQI: 4 VAS: 1
Patient 4	F/67 Response	04/2009	20/10/20 ‡ 23 weeks	TCS Antihistamines Antidepressant	Bexarotene INF-α CHOP	Before treatment: DLQI: 23 VAS: 8 After treatment: DLQI: 4 VAS: 1

†This patient showed a good initial response, but by the 12^th day he stopped responding to Aprepitant ‡The treatment was interrupted for two weeks Abbreviations: F: Female; M: Male; TCS: Topical Corticosteroids; PUVA: Phototherapy UVA; CVP: Cyclophosphamide, Vincristine, and Prednisone; INF-α: Interferon α; CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Table 1: Representative table of patients treated with Aprepitant.